Lipidic matrix of albendazole: An alternative for systemic infections

Bollettino Chimico Farmaceutico

Volumn 137, Issue 9, 1998, Pages 345-349

  Savio, E ^a   Dominguez L ^a   Malanga, A ^a   Quevedo, D ^a   Saldana J ^a   Camarote, C ^a   Ochoa, A ^a   Fagiolino, P ^a  

^a Faculty of Chemistry   (Uruguay)

Author keywords

Albendazole (ABZ); Albendazole sulphoxide (ABZS); Bioavailability; Gelucires; Hydatid disease; Lipidic matrix (LM)

Indexed keywords

ALBENDAZOLE; LIPID; MACROGOL DERIVATIVE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG SOLUBILITY; ECHINOCOCCOSIS; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADULT; ALBENDAZOLE; ANIMALS; ANTHELMINTICS; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG STABILITY; ECHINOCOCCOSIS; HUMANS; POLYETHYLENE GLYCOLS;

EID: 0344972966     PISSN: 00066648     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Ammann R., Tschudi K, Von Ziegler M, Meister F, Cotting J, Eckert J, Witassek F. and Freiburghaus A., Klin. Wochnschr, 66, 1060 (1988).
2. Gil-Grande L.A., Rodriguez-Caabeiro F., Prieto J.G, Sanchez-Ruano J.J, Brasa C, Aguilar L., García-Hoz F., Casado N, Barcena R., Alvarez A and Dal-Ré R, The Lancet, 342, 1269 (1993).
3. Teggi A., Lastilla MG and De Rosa F., Antimicrob. agents, 37 (8), 1679 (1993).
4. Luder P.J., Siffer B., Witassek F., Meiser F. and Bircher J., Eur. J. Clin Pharmacol, 31, 443 (1986).
5. Morris D.L., Chinnery J.B., Georgiou G., Stamatakis G. and Golematis B., Gut, 28, 75 (1987).
6. Cotting J., Zeugin T, Steiger U. and Reichen J., Eur. J. Clin. Pharmacol., 38, 605 (1990).
7. USP DI, Update Volumes I and II. Ed: The United States Pharmacopeial Convention, Inc., 352 (1996).
8. Shinjuma D., Hamaguchi T., Yamanaka Y., Mizuna N and Yata N., Chem. Pharm. Bull. 33(11), 4989 (1985).
9. Shinjuma D., Hamaguchi T., Yamanaka Y., Mizuna N. and Yata N., Chem. Pharm. Bull, 33(11), 5023 (1985).
10. Trotta M., Gasco M.R. and Morel S. J., Controlled Release, 10, 237 (1989).
11. Steffens K.J. and Lich A., Eur. J. Pharm. Biopharm., 37(4), 219 (1991).
12. Savio E., Fagiolino P. Solana G., Parente E. Leon A. S.T.P. Pharm. Sci. 1(6), 379 (1991).
13. Savio E., Fagiolino P., Vazquez M. and Leon A., S.T.P. Pharma Sci., 2(5), 415 (1992).
14. AUNGST B.J., J. Pharm. Sci., 82(10), 979 (1993).
15. Djimbo M., Fell J.T., Kaus L and Moes A.J., Pharm. Belg. 39(1), 36 (1984).
16. Djimbo M., Fell J.T., Kaus L and Moes A.J. Pharm. Belg. 39(1), 43 (1984).
17. Doelker C., Doelker E., Buri P. and Waginaire L., Drug. Dev. Ind. Pharm., 12(10), 1553 (1986).
18. Howard J.R. and Gould P.L., Drug. Dev. Ind. Pharm., 13(6), 1031 (1987).
19. Vial-Bernasconi A.C., Doelker E. and Buri P., S.T.P. Pharma, 4(5), 397 (1988).
20. Kopcha M., Lordi N.G. and Tojo K.J., J. Pharm. Pharmacol. 43, 382 (1990).
21. Vila Jato J.L., Remunan C. and Martinez R., S.T.P. Pharma, 6(2), 88 (1990).
22. Ortigosa C., Gaudy D, Jacob M. and Puech A. Pharm. Acta Helv. 66(11), 311 (1991).
23. Bidah D. and J.M. Vergnaud., Int. J. Pharmaceutics, 72, 35 (1991).
24. Madkarni S.R. and Laskar P.A., Pharm. Res., 10, S-135 (1993).
25. Sutananta W., Craig D.Q.M. and Newton J.M., Pharm. Res., 10, S-127 (1993).
26. Sutananta W., Craig D.Q.M. and Newton J.M. Int. J. Pharmaceutics, 110, 75 (1994).
27. Sutananta W., Craig D.Q.M. and Newton J.M., Int. J. Pharmaceutics, 111, 51 (1994).
28. Dennis A.B., Farr S.J., Kellaway I.W., Taylor G. and Davidson R., Int. J. Pharm, 65, 85 (1990).
29. Dordunoo S.K., Ford J.L. and Rubinstein M.H. Drug. Dev. and Ind. Pharm., 17(12), 1685 (1991).
30. Dominguez L., Fagiolino P., Gordon S., Manta E., Il Farmaco, 50(10), 697 (1995).
31. Marriner S.E., Morris D.L., Bogan J., Eur. J. Clin. Pharmacol., 30, 705 (1986)